Selank Dosage Chart.

It is approved in Russia, and only in Russia (and Ukraine), where it has been a prescription anxiolytic since 2009 under the name Selank, sold as 0.15% nasal drops for anxiety states, neurasthenia and stress-related disorders. It has never been approved by the FDA, EMA, MHRA, Health Canada or the TGA, there is no DailyMed entry, and it is not a compounded prescription peptide in the US. Everything sold in Western markets is labelled research-use-only. For drug-tested athletes the position is unresolved rather than settled: Selank is not named on the WADA Prohibited List, and category S0 (non-approved substances) applies only to substances with no current approval by any governmental regulatory health authority for human therapeutic use; the Russian marketing authorisation arguably puts Selank outside that wording. In practice some anti-doping bodies still treat substances lacking Western approval as S0, so do not assume it is cleared: check Global DRO or your national anti-doping organisation before using it in a tested sport.

The nasal route is the one with all the human evidence behind it, and it is the route the Russian registration, the GAD trials and the benzodiazepine comparisons all used. It also delivers straight to the olfactory and trigeminal pathways, which is likely part of why a compound with a plasma residence measured in minutes does anything at all centrally. Injection has no dosing trial behind it (no human study has established an injected dose, efficacy or safety profile), but it gives a known, reproducible systemic dose, which is why research-peptide users prefer it and why it dominates dosage charts. If you want to be closest to the evidence, use nasal. If you want dose precision from a lyophilised vial, use subQ, but at the injectable numbers on this page, not the nasal ones.

No, and this is the single most common Selank mistake. Those figures are the amount of solution instilled into the nose, not the amount absorbed. A meaningful and unquantified share of every nasal drop runs down the pharynx or is cleared by mucociliary transport before it crosses anything. Injected subcutaneously, effectively all of it enters circulation. There is no validated conversion factor published anywhere, because no one has run the head-to-head bioavailability study in humans. Drawing 2,700 mcg into a syringe because the Russian trials used that number is a several-fold overshoot of any tested systemic exposure.

No. NA-Selank-amidate is a chemically modified analogue with an acetyl group on the N-terminus and an amide on the C-terminus, added to slow enzymatic breakdown. It is a different molecule, and a very large share of the “Selank” sold in Western research-chemical channels is actually this analogue. Every clinical trial, and the Russian registration, used plain Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, MW 751.9). NA-Selank-amidate has essentially no human data at all. Vendor pages quote confident potency ratios and half-life comparisons between the two; those numbers do not trace back to any primary literature we could find, so treat them as marketing. Check your COA for which molecule you actually bought before you copy a dose from anywhere.

Not without your prescriber knowing. The interaction with benzodiazepines is real but genuinely complicated: in rats, Selank plus diazepam produced better anxiolysis under chronic stress than either alone, while in vitro receptor work found Selank can actually block diazepam’s modulatory activity at GABA-A, suggesting overlapping but non-identical binding. Clinically, a 70-patient Russian trial deliberately combined Selank with phenazepam and found it reduced the benzodiazepine’s sedation, memory impairment, apathy and orthostatic hypotension; it was studied as a benzo-sparing adjunct, not a contraindicated combination. But “studied under supervision” is not “safe to stack unsupervised”. SSRI combinations have not been formally studied at all. Anything sedating (alcohol, Z-drugs, antihistamines) deserves the same caution.

The evidence says no on both counts, which is unusual for an anxiolytic. The Russian label explicitly states Selank does not cause drug dependence or habituation, the trials found no withdrawal syndrome and no rebound anxiety on discontinuation, and the anxiolytic effect persisted for about a week after the last dose. So cycling is not about protecting receptors. The reason the courses are structured as 14 days on with a 1 – 3 week gap is simply that this is what was studied and registered. Nobody has run a controlled trial of continuous long-term dosing, so open-ended use is uncharted territory rather than known-safe. Four weeks on, four weeks off is a reasonable injectable analogue of that.

Add bacteriostatic water slowly down the inside wall of the vial (never squirt it directly onto the powder) and swirl gently until clear rather than shaking. For a 5 mg vial, 2 mL gives 2,500 mcg/mL, so 250 mcg is 10 units, 500 mcg is 20 units and 750 mcg is 30 units on a U-100 syringe. Keep the unopened lyophilised powder at 2 – 8 °C, protected from light, and do not freeze it (the Russian label says the same for its own product). Once mixed, keep it refrigerated and use it within about 30 days. For reference, the Russian nasal formulation is only rated for 15 days after opening at room temperature, so do not leave a reconstituted vial on a nightstand.

Something measurable happens within 5 to 20 minutes (that is the fMRI finding in healthy volunteers), but most people do not consciously feel a first dose, and expecting a benzodiazepine-like onset will make you conclude your vial is fake when it is not. The realistic sequence is sleep and irritability shifting around days 2 to 5, the anxiety scores themselves moving by days 7 to 14, and the attention and mood-stability effects filling in over weeks 2 to 4. Day 14 is the honest verdict point. If 250 – 500 mcg daily for two full weeks has done nothing, the correct response is to stop, not to double the dose; the dose-response curve is flat enough that more milligrams mostly buy flatness.